Authors: | Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; Chuken, Y. A. L.; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Żotkiewicz, M.; Ali, S.; Cohen, G.; Lencioni, R. |
Abstract Title: | mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
Meeting Title: | European Association for the Study of the Liver (EASL) Congress 2024 |
Journal Title: | Journal of Hepatology |
Volume: | 80 |
Issue: | Suppl. 1 |
Meeting Dates: | 2024 Jun 5-8 |
Meeting Location: | Milan, Italy |
ISSN: | 0168-8278 |
Publisher: | Elsevier Science, Inc. |
Date Published: | 2024-06-01 |
Start Page: | S3 |
Language: | English |
ACCESSION: | WOS:001278309400006 |
PROVIDER: | wos |
DOI: | 10.1016/S0168-8278(24)00428-8 |
Notes: | Meeting Abstract: GS-005 -- Source: Wos |